Quest Diagnostics Ups FY Rev Guidance as 2Q Profit, Rev Rise

Dow Jones

2025/07/22

By Adriano Marchese

Quest Diagnostics raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter.

The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion.

Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share.

In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago.

Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share.

Revenue rose 15% to $2.76 billion, which includes 5.2% growth from organic revenues, beating expectations of a rise to $2.73 billion.

Chairman and Chief Executive Jim Davis said the company benefited from demand for clinical solutions and expanded business from enterprise accounts that complemented growth from acquisitions.

"We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance," Davis said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

July 22, 2025 07:33 ET (11:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553556732"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553556732\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553556732?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553556732","market":"hk","top_or_hot":-1,"title":"Quest Diagnostics Ups FY Rev Guidance as 2Q Profit, Rev Rise","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DGX\">Quest Diagnostics</a> raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter. \n</p>\n<p>\n  The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion. \n</p>\n<p>\n  Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share. \n</p>\n<p>\n  In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago. \n</p>\n<p>\n  Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share. \n</p>\n<p>\n  Revenue rose 15% to $2.76 billion, which includes 5.2% growth from organic revenues, beating expectations of a rise to $2.73 billion. \n</p>\n<p>\n  Chairman and Chief Executive Jim Davis said the company benefited from demand for clinical solutions and expanded business from enterprise accounts that complemented growth from acquisitions. \n</p>\n<p>\n  \"We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance,\" Davis said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2025 07:33 ET (11:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quest Diagnostics Ups FY Rev Guidance as 2Q Profit, Rev Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuest Diagnostics Ups FY Rev Guidance as 2Q Profit, Rev Rise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-22 19:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/DGX\">Quest Diagnostics</a> raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter. \n</p>\n<p>\n  The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion. \n</p>\n<p>\n  Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share. \n</p>\n<p>\n  In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago. \n</p>\n<p>\n  Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share. \n</p>\n<p>\n  Revenue rose 15% to $2.76 billion, which includes 5.2% growth from organic revenues, beating expectations of a rise to $2.73 billion. \n</p>\n<p>\n  Chairman and Chief Executive Jim Davis said the company benefited from demand for clinical solutions and expanded business from enterprise accounts that complemented growth from acquisitions. \n</p>\n<p>\n  \"We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance,\" Davis said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 22, 2025 07:33 ET (11:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1854104046.USD","symbol_name":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2553556732","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553556732","pubTimestamp":1753183980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Quest Diagnostics raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter.The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion.Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share.In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago.Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share.\"We also realized productivity gains as we continued to deploy automation and digital techno","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","DGX":"奎斯特诊疗","BK4583":"猴痘概念","BK4588":"碎股","BK4196":"保健护理服务","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC"},"translate_title":"随着第二季度利润和营业额上升，Quest Diagnostics上调财年营业额指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DGX":1},"content_text":"By Adriano Marchese \n\n\n \n\n\nQuest Diagnostics raised its revenue guidance for the full year on higher demand and productivity gains after seeing profit and revenue growth in the second quarter. \n\n\n  The provider of diagnostic information services raised its revenue view for the full year to $10.8 billion to $10.92 billion, up from a previous expectation of between $10.7 billion and $10.85 billion. \n\n\n  Earnings, however, are expected lower, now projected to be between $8.60 and $8.80 a share, compared with the previous forecast for $8.62 to $8.87 a share. On an adjusted basis, the new range is for earnings to be between $9.63 and $9.83 a share, up from a previous range of $9.55 and $9.80 a share. \n\n\n  In the second quarter, net income came to $282 million, or $2.47 a share, up from $229 million, or $2.03 a share, in the same quarter a year ago. \n\n\n  Adjusted earnings were $2.62 a share. According to FactSet, analysts were expecting $2.57 a share. \n\n\n  Revenue rose 15% to $2.76 billion, which includes 5.2% growth from organic revenues, beating expectations of a rise to $2.73 billion. \n\n\n  Chairman and Chief Executive Jim Davis said the company benefited from demand for clinical solutions and expanded business from enterprise accounts that complemented growth from acquisitions. \n\n\n  \"We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance,\" Davis said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 22, 2025 07:33 ET (11:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}